Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

ER-464195-01

Catalog No. T213104 Copy Product Info
🥰Excellent
ER-464195-01 is an orally active inhibitor that targets the interaction between CRT and ITGAs. By disrupting the binding of CRT and ITGAs, ER-464195-01 reduces leukocyte infiltration and subsequent inflammatory cascade reactions. It downregulates the expression of pro-inflammatory genes induced by DSS, such as [TNF-α], [IL-1β], [IL-6], [IL-17f], and inhibits the phosphorylation of STAT3 and the production of serum amyloid A (SAA). This compound is applicable for research in inflammatory bowel disease (IBD).

ER-464195-01

Copy Product Info
🥰Excellent
Catalog No. T213104

ER-464195-01 is an orally active inhibitor that targets the interaction between CRT and ITGAs. By disrupting the binding of CRT and ITGAs, ER-464195-01 reduces leukocyte infiltration and subsequent inflammatory cascade reactions. It downregulates the expression of pro-inflammatory genes induced by DSS, such as [TNF-α], [IL-1β], [IL-6], [IL-17f], and inhibits the phosphorylation of STAT3 and the production of serum amyloid A (SAA). This compound is applicable for research in inflammatory bowel disease (IBD).

ER-464195-01
Cas No. 859218-37-4
Pack SizePriceUSA StockGlobal StockQuantity
10 mgInquiry10-14 weeks10-14 weeks
50 mgInquiry10-14 weeks10-14 weeks
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
ER-464195-01 is an orally active inhibitor that targets the interaction between CRT and ITGAs. By disrupting the binding of CRT and ITGAs, ER-464195-01 reduces leukocyte infiltration and subsequent inflammatory cascade reactions. It downregulates the expression of pro-inflammatory genes induced by DSS, such as [TNF-α], [IL-1β], [IL-6], [IL-17f], and inhibits the phosphorylation of STAT3 and the production of serum amyloid A (SAA). This compound is applicable for research in inflammatory bowel disease (IBD).
In vitro
ER-464195-01 (5 μM) effectively inhibits the interaction between CRT and ITGA4 within Jurkat cells and significantly reduces the level of CRT on the cell surface. Additionally, ER-464195-01 (0.01-10 μM, 60 minutes) suppresses the adhesion capability of VCAM-1 cells stimulated by PMA and ICAM-1 cells stimulated by fMLP, with IC50 values of 0.15 μM and 0.19 μM, respectively, while showing no inhibitory effect under MnCl2 stimulation.
In vivo
ER-464195-01, administered orally at 5-10 mg/kg once daily for 6-32 consecutive days, effectively reduces disease severity in mouse models of inflammatory bowel disease (IBD) when used for both prevention and treatment.
Chemical Properties
Molecular Weight379.03
FormulaC23H39ClN2
Cas No.859218-37-4
SmilesCl.C=1C=CC(=C(C1)N2CCN(CC2)CCC)C3CC(C)(C)CC(C)(C)C3
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy ER-464195-01 | purchase ER-464195-01 | ER-464195-01 cost | order ER-464195-01 | ER-464195-01 in vivo | ER-464195-01 in vitro | ER-464195-01 formula | ER-464195-01 molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.